ISPOR Comments on Health Policies
ISPOR COMMENTS ON HEALTHCARE POLICIES
ISPOR Comments on US Comparative Effectiveness Program (April 2008)
ISPOR COMMENTS ON RESEARCH POLICIES
» JAMA Policy on Data Access and Responsibility (June 2006) » JAMA Responds to ISPOR's Comments on Data Access and Responsibility
» FDA Guidance for Industry – Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (December 2009) » FDA Guidance for Industry – Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims – DRAFT GUIDANCE (February 2006) » EMEA HRQL Guidance (July 2005)
» FDA Risk Management Concept Paper (April 2003) » FDA Risk Management Workshop announcement
» FDA draft Guidance on Economic Information for Promotional Use » FDAMA Section 114 Debriefing Conference
Contact ISPOR @ info@ispor.org | View Legal Disclaimer ©2010 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. Website design by Eagle Systems USA, Inc.